full-text âº
National Guideline Clearinghouse | Consensus treatment recommendations for late-onset Pompe disease.
December 31, 2012
Cupler EJ, Berger KI, Leshner RT, Wolfe GI, Han JJ, Barohn RJ, Kissel JT, AANEM Consensus Committee on Late-onset Pompe Disease. Consensus treatment recommendations for late-onset Pompe disease. Muscle Nerve 2012 Mar;45(3):319-33. [108 references] PubMed ![]() |
Consensus treatment recommendations for late-onset Pompe disease.
Source
Department of Neurology, Oregon Health & Science University, Portland, Oregon, USA.
Abstract
INTRODUCTION:
Pompe disease is a rare, autosomal recessive disorder caused by deficiency of the glycogen-degrading lysosomal enzyme acid alpha-glucosidase. Late-onset Pompe disease is a multisystem condition, with a heterogeneous clinical presentation that mimics other neuromuscular disorders.
METHODS:
Objective is to propose consensus-based treatment and management recommendations for late-onset Pompe disease.
METHODS:
A systematic review of the literature by a panel of specialists with expertise in Pompe disease was undertaken.
CONCLUSIONS:
A multidisciplinary team should be involved to properly treat the pulmonary, neuromuscular, orthopedic, and gastrointestinal elements of late-onset Pompe disease. Presymptomatic patients with subtle objective signs of Pompe disease (and patients symptomatic at diagnosis) should begin treatment with enzyme replacement therapy (ERT) immediately; presymptomatic patients without symptoms or signs should be observed without use of ERT. After 1 year of ERT, patients’ condition should be reevaluated to determine whether ERT should be continued.
Copyright © 2011 Wiley Periodicals, Inc.
- PMID:
- 22173792
- [PubMed - indexed for MEDLINE]Â
Consensus treatment recommendations for late-on… [Muscle Nerve. 2012] – PubMed – NCBI
没有评论:
发表评论